Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Extension Study to Assess the Safety and Efficacy of GLM101 Administered Intravenously to Participants With PMM2-CDG

NCT06657859 is registered in ClinicalTrials.gov with Glycomine, Inc. as lead sponsor.

NCT NCT06657859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06657859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Extension Study to Assess the Safety and Efficacy of GLM101 Administered Intravenously to Participants With PMM2-CDG
Lead sponsor
Glycomine, Inc.
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
September 30, 2024
Completion date
October 31, 2029
Enrollment
90 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

phosphomannomutase 2 deficiency, pmm2-cdg